Prospects for updates on the field of liver surgery in “Guidelines for Diagnosis and Treatment of Primary Hepatocellular Carcinoma in China (2019 Edition)”

doi:10.16139/j.1007-9610.2020.01.002

Abstract

CLC Number:

R735.7

HUANG Cheng, SUN Huichuan. Prospects for updates on the field of liver surgery in “Guidelines for Diagnosis and Treatment of Primary Hepatocellular Carcinoma in China (2019 Edition)”[J]. Journal of Surgery Concepts & Practice, 2020, 25(01): 6-9.

References 19

[1]	Mohkam K, Dumont PN, Manichon AF, et al. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm[J]. J Hepatol, 2018, 68(6):1172-1180.
[2]	Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24):2141-2151.
[3]	Xiao H, Zhang B, Mei B, et al. Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablation[J]. Medicine (Baltimore), 2015, 94(7):e495.
[4]	Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260(2):329-340.
[5]	Chen X, Zhai J, Cai X, et al. Severity of portal hypertension and prediction of postoperative liver failure after li-ver resection in patients with Child-Pugh grade A cirrhosis[J]. Br J Surg, 2012, 99(12):1701-1710. doi: 10.1002/bjs.8951 pmid: 23132418
[6]	Li XL, Zhu XD, Cai H, et al. Postoperative alpha-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis[J]. Surgery, 2019, 165(6):1161-1167.
[7]	Yang J, Tao HS, Cai W, et al. Accuracy of actual resec-ted liver volume in anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imaging[J]. J Surg Oncol, 2018, 118(7):1081-1087.
[8]	Mise Y, Hasegawa K, Satou S, et al. How has virtual hepatectomy changed the practice of liver surgery? experience of 1194 virtual hepatectomy before Liver resection and living donor liver transplantation[J]. Ann Surg, 2018, 268(1):127-133.
[9]	Wu X, Huang Z, Lau WY, et al. Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic background: a propensity score matching study[J]. Surg Endosc, 2019, 33(1):206-215.
[10]	Cheung TT, Han HS, She WH, et al. The Asia Pacific consensus statement on laparoscopic liver resection for hepatocellular carcinoma: a report from the 7th Asia-Pacific primary liver cancer expert meeting held in Hong Kong[J]. Liver Cancer, 2018, 7(1):28-39. doi: 10.1159/000481834 pmid: 29662831
[11]	Wang Z, Peng Y, Hu J, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients[J]. Ann Surg, 2018. Jul10.doi: 10.1097/SLA.0000000000002942.[Epub ahead of print] doi: 10.1097/SLA.0000000000002942 URL
[12]	He MK, Zou RH, Li QJ, et al. Phase Ⅱ study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis[J]. Cardiovasc Intervent Radiol, 2018, 41(5):734-743.
[13]	Yang P, Si A, Yang J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion[J]. Surgery, 2019, 165(4):721-730.
[14]	Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study[J]. Clin Cancer Res, 2018, 24(9):2074-2081.
[15]	Wei W, Jian PE, Li SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for he-patocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety[J]. Cancer Commun (Lond), 2018, 38(1):61.
[16]	Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial[J]. Gut, 2018, 67(11):2006-2016.
[17]	Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4):203-217. doi: 10.1038/nrgastro.2016.193 pmid: 28053342
[18]	Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis[J]. Hepatology, 2018, 67(1):381-400.
[19]	Pinheiro RS, Waisberg DR, Nacif LS, et al. Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?[J]. Transl Gastroenterol Hepatol, 2017, 2:68. doi: 10.21037/tgh.2017.08.02 pmid: 28905009

Prospects for updates on the field of liver surgery in “Guidelines for Diagnosis and Treatment of Primary Hepatocellular Carcinoma in China (2019 Edition)”

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 19

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YE Feng, GONG Xiaoyong, REN Jiajun, CAI Qiang, CHEN Sheng. Application of ERCP in diagnosis and treatment of biliary complications during perioperative period of primary liver cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 355-360.
[2]	CHANG Jessica, CHEN Xuxiao, CHEN Yongjun. Role of the spleen in patients with liver cancer and cirrhosis [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 394-398.
[3]	ZHANG Hui, GONG Ling, GUO Qian, LUO Yan. Retrospective study on sugammadex for reversal of neuromuscular blockade after radiofrequency ablation of hepatic carcinoma under general anesthesia [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 72-76.
[4]	ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing. Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482.
[5]	YIN Yanjiang, LUO Zhiwen, CHEN Xiao, ZHANG Yefan, HUANG Zhen, ZHAO Hong, ZHAO Jianjun, LI Zhiyu, ZHOU Jianguo, CAI Jianqiang, BI Xinyu. Relationship between surgical margin and prognosis of patients with intrahepatic cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 221-228.
[6]	CHEN Congyan, WANG Junqing, CHEN Yongjun. Gut microbiota and mechanism of liver cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 256-260.
[7]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 93-94.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 95-99.
[9]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 100-106.
[10]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 107-112.
[11]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 113-118.
[12]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 119-122.
[13]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 123-127.
[14]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 128-130.
[15]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 131-133.